Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifitegrast in Dry Eye Disease (OPUS-1)
NCT01421498Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing 5.0% Lifitegrast with Placebo (2 arms). Primary endpoints: Inferior Corneal Fluorescein Staining Score at Day 84 and Visual-Related Subscale of the Ocular Surface Disease Index at Day 84. Started Aug 2011; status: completed.
02
Drugs
lifitegrast
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT01421498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421498.